BATON ROUGE, July 10 — A clinical trial funded by the National Institutes of Health remains the most rigorous human test of caloric restriction, and its results, published in 2015, show measurable biomarker improvements but no data on lifespan extension. The CALERIE trial — the Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy — was a multi-center randomized controlled study running from 2007 to 2012. It enrolled 218 non-obese adults aged 21 to 50.
Participants cut their calorie intake by 25 percent for two years. Dr. Eric Ravussin at the Pennington Biomedical Research Center in Baton Rouge led the study.
The findings, published in The Journals of Gerontology, documented a reduction in systolic blood pressure by an average of 4 mmHg. LDL cholesterol dropped by 6 mg/dL. But the trial did not measure lifespan.
No significant change in lifespan metrics was reported. The scientific record on caloric restriction goes back decades.
In 1935, Clive McCay at Cornell University demonstrated that restricting calories in rats increased their lifespan by up to 33 percent. That finding established a foundation for decades of subsequent animal research. Later primate studies produced mixed results.
A 2009 study led by Dr. Richard Weindruch at the University of Wisconsin found that rhesus monkeys on caloric restriction showed improved healthspan — the period of life free from serious disease — but did not achieve a statistically significant extension of overall lifespan. A 2012 study conducted by the National Institute on Aging found no lifespan benefit at all in rhesus monkeys. The core intervention — caloric restriction — involves reducing total daily calorie intake by 20 to 40 percent while avoiding malnutrition.
In animal models, the consistency of lifespan extension has been striking. In rats, the 1935 McCay study recorded that one-third increase in lifespan.
But the translation to humans remains uncertain.
Adherence and advocacy
Critics of the human data point to a fundamental problem: long-term adherence. Sustaining a 25 percent calorie reduction for years is difficult. The CALERIE trial lasted two years; the long-term effects on human lifespan remain unknown.
The CR Society International, founded in 1994, advocates for the practice. Its membership is estimated at under 10,000 globally — a small community by any measure.
The gap between animal and human results is a central tension in the field. In rodents, the lifespan extension is large and reproducible. In non-human primates, the data are contradictory.
In humans, the best available trial shows improved biomarkers but no lifespan data at all. Researchers continue to examine whether the metabolic changes observed in CALERIE — lower blood pressure, reduced cholesterol — might translate into delayed aging or reduced mortality over a full lifetime.
No study has yet answered that question.
What the record shows
The source material for this report is the published record of the CALERIE trial, the 1935 McCay rat study, the 2009 Wisconsin monkey study led by Weindruch, the 2012 NIA monkey study, and the membership data for the CR Society International. All figures cited appear in those documents. On the timeline: the foundational animal work began in 1935.
The primate studies came in 2009 and 2012. The human CALERIE trial ran from 2007 to 2012, with results published in 2015.
The CR Society was founded in 1994. No human study has demonstrated that caloric restriction extends lifespan. The biomarker improvements are real.
The long-term effects on mortality are unknown. Consult your doctor for medical advice.
